Genomic Health Announces Medicare Expanded Coverage Policy for Oncotype DX®; Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD Print E-mail
By Staff and Wire Reports   
Friday, 10 May 2013 19:05
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 10, 2013.

Genomic Health, Inc. (Nasdaq: GHDX) announced Palmetto GBA, the designated national contractor for its Oncotype DX® breast cancer test, has expanded its coverage policy for all qualified Medicare patients to include patients with ductal carcinoma in situ (DCIS) following the recent publication of the breast cancer test's DCIS Score in the peer-reviewed, Journal of the National Cancer Institute.

The detection of DCIS is increasing in the United States, with more than 50,000 patients diagnosed each year. Most women with DCIS who receive breast-conserving surgery without standard radiotherapy will not develop a local recurrence, defined as either the recurrence of DCIS or the development of a new invasive cancer in the same breast. The Oncotype DX DCIS Score predicts 10-year local recurrence, DCIS or invasive carcinoma,  based on a patient's individualized underlying tumor biology regardless of whether adjuvant tamoxifen is given, providing important information beyond traditional clinical factors such as tumor size, grade, surgical margins, or menopausal status.


======


GlaxoSmithKline plc (NYSE: GSK)
and Theravance, Inc. (NASDAQ: THRX) announced the US FDA has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).


Also Friday:


Actavis, Inc. (NYSE: ACT)
, a global specialty pharmaceutical leader, today confirmed that Actavis has entered into early stage discussions with Warner Chilcott plc (Nasdaq: WCRX) regarding a potential combination of the two companies.  

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)
announcedtoday that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 2:20 p.m. Pacific Time (5:20 p.m. Eastern Time), at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada.

Arrhythmia Research Technology, Inc. (NYSE MKT: HRT)
(the Company) announces positive results of the Company's Signal-Averaged Electrocardiography (SAECG) technology employed in a multi-center clinical trial that studied 484 patients with prior myocardial infarction (heart attack).

Cancer Genetics, Inc. (OTCQB: CGIX)
("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will hold a conference call on Thursday, May 16, 2013, at 9:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2013.

CleanPath Resources Corp (OTC Pink: CLNP)
(www.re-load.biz) CleanPath Resources' newest research and development partner, BioSwan, Inc., just announced new research initiatives for its stem cell enhancement  product  NutraLoad™.

Discovery Laboratories, Inc. (NASDAQ: DSCO)
today announced that it has priced an underwritten public offering of 9.5 million shares of its common stock, at a price to the public of $1.50 per share for gross proceeds of $14.25 million.

Elekta (NSE: EKTAb)
and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy.

Genomic Health, Inc. (Nasdaq: GHDX)
today announced that, effective May 8, 2013, Palmetto GBA, the designated national contractor for its Oncotype DX® breast cancer test, has expanded its coverage policy for all qualified Medicare patients to include patients with ductal carcinoma in situ (DCIS) following the recent publication of the breast cancer test's DCIS Score in the peer-reviewed, Journal of the National Cancer Institute.

Digirad Corporation (NASDAQ: DRAD)
today announced the final shareholder voting results from the Company's Annual Meeting of Stockholders, which was held on May 3, 2013.

Impax Laboratories, Inc. (NASDAQ: IPXL)
today announced that the Company will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, at 8:00 a.m. Pacific Standard Time.

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO)
today reported financial results for the quarter ended March 31, 2013.

Insmed Incorporated (NASDAQ: INSM)
("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will be presenting a corporate overview at Bank of America Merrill Lynch 2013 Health Care Conference taking place from May 14-16, 2013 at the Encore at the Wynn in Las Vegas, NV.

Medicure Inc. (the "Company") (TSX VENTURE:MPH) (PINKSHEETS:MCUJD)
announces today that the Board of Directors has approved the grant of an aggregate of 463,000 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan.

Omeros Corporation (NASDAQ: OMER)
, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2013.

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
announced today that all nominees listed in the management information circular dated April 4, 2013 were elected as directors at its 2013 Annual and Special Meeting of Shareholders, held on Thursday, May 9th, 2013.

OphthaliX, Inc. (OTC BB: OPLI)
, announced today that it has come to its knowledge that Professor M. Francesca Cordeiro, a Professor of Glaucoma & Retinal Neurodegeneration Studies from UCL and Imperial College in London, presented new data generated independently and unrelated to OphthaliX, validating the utilization of the A3 adenosine receptor (A3AR) agonists for lowering intra ocular pressure (IOP) and for the treatment of Glaucoma, during the ARVO 2013 Annual Meeting in Seattle, Washington, which took place from May 5th - 9th 2013.

Orexigen® Therapeutics, Inc. (Nasdaq: OREX)
today announced that management will present a company overview at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.

Parametric Sound Corporation (NASDAQ: PAMT)
, a leading innovator of audio products and solutions, today announced that Jim Barnes, Chief Financial Officer, will present at the East Coast IDEAS Investor Conference on Wednesday, May 15, 2013 at the Metro Meeting Center in Boston, Massachusetts.

Santarus, Inc. (NASDAQ: SNTS)
today announced the pricing of a secondary underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $18.25 per share.

Telik, Inc. (Nasdaq: TELK)
today reported financial results for the first quarter ended March 31, 2013.  The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or $1.25 per share, for the same period in 2012.

Yongye International, Inc. (NASDAQ: YONG)
, ("Yongye" or the "Company") a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), today announced its financial results for the quarter ended March 31, 2013.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter